Pila Pharma enrolls first participant in PP-CT04 obesity trial of XEN-D0501
Bitget2026/09/30 15:18- Pila Pharma launched dosing for Part 1 of PP-CT04, a 12-week obesity trial of oral candidate XEN-D0501.
- No clinical results have been presented; Part 2 is slated to start once Part 1 clears an internal safety review.
- The study aims to assess safety and tolerability, with additional readouts on drug exposure and efficacy.
- Part 1 uses an eight-participant pilot cohort with intensified safety monitoring before broader enrollment proceeds.
- Dosing uses individual titration to higher target exposures, seeking levels not previously tested in the program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Circle issues 500 million USDC on the Solana network

Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.
